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Melanoma cells express the chemokine receptor CXCR4 that
confers high invasiveness upon binding to its ligand CXCL12.
Melanoma cells at initial stages of the disease show reduction or
loss of E-cadherin expression, but recovery of its expression is
frequently found at advanced phases. We overexpressed E-cad-
herin in the highly invasive BRO lungmetastatic cell melanoma
cell line to investigate whether it could influence CXCL12-pro-
moted cell invasion. Overexpression of E-cadherin led to defec-
tive invasion ofmelanoma cells acrossMatrigel and type I colla-
gen in response to CXCL12. A decrease in individual cell
migration directionality toward the chemokine and reduced
adhesion accounted for the impaired invasion. A p190RhoGAP-
dependent inhibition of RhoA activationwas responsible for the
impairment in chemokine-stimulated E-cadherin melanoma
transfectant invasion. Furthermore, we show that p190RhoGAP
and p120ctn associated predominantly on the plasma mem-
brane of cells overexpressing E-cadherin, and that E-cadherin-
bound p120ctn contributed to RhoA inactivation by favoring
p190RhoGAP-RhoA association. These results suggest that
melanoma cells at advanced stages of the disease could have
reduced metastatic potency in response to chemotactic stimuli
comparedwith cells lacking E-cadherin, and the results indicate
that p190RhoGAP is a central molecule controlling melanoma
cell invasion.
Cadherins are a family of Ca2-dependent adhesion mole-
cules that mediate cell-cell contacts and are expressed in most
solid tissues providing a tight control of morphogenesis (1, 2).
Classical cadherins, such as epithelial (E) cadherin, are found in
adherens junctions, forming core protein complexes with
-catenin, -catenin, and p120 catenin (p120ctn). Both -cate-
nin and p120ctn directly interact with E-cadherin, whereas
-catenin associates with the complex through its binding to
-catenin, providing a link with the actin cytoskeleton (1, 2).
E-cadherin is frequently lost or down-regulated inmanyhuman
tumors, coincident withmorphological epithelial tomesenchy-
mal transition and acquisition of invasiveness (3–6).
Although melanoma only accounts for 5% of skin cancers,
when metastasis starts, it is responsible for 80% of deaths from
skin cancers (7). Melanocytes express E-cadherin (8–10), but
melanoma cells at early radial growth phase show a large reduc-
tion in the expression of this cadherin, and surprisingly, expres-
sion has been reported to be partially recovered by vertical
growth phase and metastatic melanoma cells (9, 11, 12).
Trafficking of cancer cells from primary tumor sites to
intravasation into blood circulation and later to extravasation
to colonize distant organs requires tightly regulated directional
cues and cell migration and invasion that are mediated by che-
mokines, growth factors, and adhesion molecules (13). Solid
tumor cells express chemokine receptors that provide guidance
of these cells to organs where their chemokine ligands are
expressed, constituting a homing model resembling the one
used by immune cells to exert their immune surveillance func-
tions (14). Most solid cancer cells express CXCR4, a receptor
for the chemokine CXCL12 (also called SDF-1), which is
expressed in lungs, bone marrow, and liver (15). Expression of
CXCR4 in human melanoma has been detected in the vertical
growth phase and on regional lymph nodes, which correlated
with poor prognosis and increased mortality (16, 17). Previous
in vivo experiments have provided evidence supporting a cru-
cial role for CXCR4 in the metastasis of melanoma cells (18).
Rho GTPases control the dynamics of the actin cytoskeleton
during cell migration (19, 20). The activity of Rho GTPases is
tightly regulated by guanine-nucleotide exchange factors
(GEFs),4 which stimulate exchange of bound GDP by GTP, and
inhibited by GTPase-activating proteins (GAPs), which pro-
mote GTP hydrolysis (21, 22), whereas guanine nucleotide dis-
sociation inhibitors (GDIs) appear tomediate blocking of spon-
taneous activation (23). Therefore, cell migration is finely
regulated by the balance betweenGEF, GAP, andGDI activities
on RhoGTPases. Involvement of RhoGTPases in cancer is well
documented (reviewed in Ref. 24), providing control of both
cell migration and growth. RhoA and RhoC are highly
expressed in colon, breast, and lung carcinoma (25, 26),
whereas overexpression of RhoC in melanoma leads to
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enhancement of cell metastasis (27). CXCL12 activates both
RhoA and Rac1 in melanoma cells, and both GTPases play key
roles during invasion toward this chemokine (28, 29).
Given the importance of the CXCL12-CXCR4 axis in mela-
noma cell invasion and metastasis, in this study we have
addressed the question of whether changes in E-cadherin
expression on melanoma cells might affect cell invasiveness.
We show here that overexpression of E-cadherin leads to
impaired melanoma cell invasion to CXCL12, and we provide
mechanistic characterization accounting for the decrease in
invasion.
EXPERIMENTAL PROCEDURES
Cells, Antibodies, and Reagents—BLM human melanoma
cells were cultured as described previously (28). Anti-E-cad-
herin antibodies were provided by Dr. Amparo Cano (Instituto
de Investigaciones Biome´dicas, Madrid, Spain) and were also
purchased from R & D Systems (Minneapolis, MN). Anti--
catenin antibodies were from Cell Signaling Technology (Dan-
vers, MA); anti--catenin, anti-p120ctn, and anti-Rac1 were
from Pharmingen; anti-RhoA and anti-phosphotyrosine PY20
were from Santa Cruz Biotechnology (Santa Cruz, CA); anti-
vinculin and anti--actin were from Sigma; anti-GFP was from
Molecular Probes (Eugene, OR); anti-p190RhoGAP was from
Upstate Biotechnology, Inc. (Lake Placid, NY); and anti-
CXCR4 was from R & D Systems. We also obtained anti-
p120ctn antibodies from Dr. Albert B. Reynolds (Vanderbilt
University, Nashville, TN), whereas control P3X63 and anti-1
integrin Lia1/2.1 were provided by Dr. Francisco Sa´nchez-Ma-
drid (Hospital de la Princesa, Madrid, Spain). Alexa 633-phal-
loidin was purchased from Molecular Probes; fibronectin was
from Roche Diagnostics, and Src inhibitors PP2 and PP3 were
from Calbiochem-Novabiochem.
Vectors, siRNA, Transfections, and Infections—The E-cad-
herin expression vector pBAT-EM2 and the empty vector
pBAT-neo were gifts from Dr. Amparo Cano. Vectors coding
for GFP-fused forms of wild type RhoA and Rac1 and activated
V14-RhoA and V12-Rac1 were gifts from Dr. Francisco
Sa´nchez-Madrid, and pEGFP-p190RhoGAP and pEGFP-
p120ctn vectors were from Dr. Keith Burridge (University of
North Carolina, Chapel Hill). A pool of siRNA for E-cadherin
(ON-TARGETplus SMARTpool) and two siRNAs against
p190RhoGAP, p190A(1), and p190A(2) (siGENOME duplex
D-004158-03 and -04, respectively) were purchased fromDhar-
macon Inc. (Chicago, IL), whereas siRNA for p120ctn was from
Ambion Inc. (Austin, TX). We used a control siRNA as earlier
described (30). BLMcells were transfectedwith expression vec-
tors or siRNA (100 nM) using Lipofectamine reagent (Invitro-
gen) or X-tremeGENE (Roche Diagnostics), respectively, as
reported previously (30). Transfectants were tested in the dif-
ferent assays 48 h post-transfection. When GFP-expressing
transfectants were used, cells were analyzed by flow cytometry
to assess transfection efficiency, which was consistently higher
than 85% (data not shown). The different E-cadherin sublines
generated upon pBAT-EM2 or pBAT-neo transfection into
BLM cells were obtained by limit dilution, and transfectants
were selected with G418 (Invitrogen). Wild type E-cadherin
and the mutant 764AAA E-cadherin form in pLZRS vectors
were gifts of Dr. Albert B. Reynolds. These vectors were co-
transfected with pNGVL-VSV-G and pNGVL-gag-pol vectors
in 293FT cells as reported previously (31). Conditioned media
containing viral particles were used to infect BLM cells that
were selected with G418. Expression of E-cadherin was
assessed by flow cytometry.
Invasion and Adhesion Assays—Invasions were done as ear-
lier established (29). Briefly, cells on the upper compartments of
Matrigel-coatedTranswells (Falcon) were allowed to invade for
22 h to the lower compartments filled with invasion medium
with or without CXCL12. Invasive cells were fixed, stained, and
counted under a microscope. For adhesion assays, cells were
first labeled with 2,7-bis(carboxyethyl)-5(6)-carboxyfluores-
cein-acetoxymethyl ester (Molecular Probes) and loaded (3 
104) in triplicate on 96-well dishes (Costar, Cambridge, MA)
previously coated withMatrigel (1g/ml) (Falcon), collagen IV
(2 g/ml), or fibronectin (8 g/ml) (Sigma). Cells were allowed
to adhere for 10 min at 37 °C, followed by three washes with
Dulbecco’s modified Eagle’s medium to remove unbound cells.
Adhesion was quantified using a fluorescence analyzer
(POLARstar Galaxy; Offenburg, Germany).
Time-lapse Microscopy—-Slide chemotaxis chambers
(Ibidi, Martinsried, Germany) were coated with Matrigel (0.1
mg/ml) in Dulbecco’s modified Eagle’s medium. 6 l of cell
suspensions (2 106 cells/ml) were applied into the slide chan-
nel and incubated for 1 h in a humid atmosphere. Following cell
attachment, chamber reservoirs were filled with Dulbecco’s
modified Eagle’s medium, and CXCL12 (300 ng/ml) was added
in the upper reservoir according to the manufacturer’s instruc-
tions. Immediately after, the chambers were mounted on the
stage of an inverted Live Cell Imaging microscope (Leica
AF6000 LX type DMI6000B), and cell movement was recorded
using a 10 objective of bright field (2 min each frame for 5 h)
in temperature- andCO2-controlled chambers. Tracks from 30
cells were determined with Manual Tracking (ImageJ plug-in,
National Institutes of Health), and the effect of CXCL12 to cell
directionality was analyzed with Chemotaxis and Migration
Tool (ImageJ plug-in, Ibidi). Cell directionality was assessed as
the ratio of Euclidean mean distance (EMD) versus accumu-
lated mean distance (AMD).
Cell Fractionation—Following detachment with 2mMEDTA
in PBS, cells were resuspended in hypotonic buffer (Tris-HCl,
pH 7.5, 5 mM, NaCl 10 mM, MgCl2 0.5 mM, EGTA 1 mM, dithi-
othreitol 1 mM, digitonin 40 g/ml, aprotinin 5 g/ml, leupep-
tin 10g/ml, phenylmethylsulfonyl fluoride 1mM, andNa3VO4
1 mM). Cell extracts were centrifuged, and supernatants (cyto-
plasmic fraction) were kept until use, whereas pellets (mem-
brane fraction) were washed with PBS and resuspended in lysis
buffer (Tris-HCl, pH 7.5, 10 mM, NaCl 40 mM, MgCl2 1 mM,
dithiothreitol 1mM, Nonidet P-40 0.2%, aprotinin 5g/ml, leu-
peptin 10 g/ml, phenylmethylsulfonyl fluoride 1 mM, and
Na3VO4 1 mM). Upon centrifugation, supernatants containing
membrane proteins were collected for further analyses.
Immunoprecipitation, Western Blotting, and GTPase Assays—
For immunoprecipitation, melanoma cells were lysed as earlier
described (30), and extracts were incubatedwith antibodies fol-
lowed by specific coupling to protein A-Sepharose beads
(Amersham Biosciences). Proteins were eluted in Laemmli
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buffer, resolved by SDS-PAGE, and subjected toWestern blot-
ting with primary antibodies, followed by incubation with
horseradish peroxidase-conjugated secondary antibodies and
detection with SuperSignal chemiluminescent substrate
(Pierce). GTPase activity assays were performed as reported
previously (29). In brief, cells were detached with EDTA-con-
taining PBS and incubated in suspension with or without
CXCL12, and upon cell lysis, aliquots from extracts were kept
for total lysate controls, and the remaining volume was incu-
bated with GST-C21 (for RhoA) or GST-PAK-CD (for Rac1)
fusion proteins (32) in the presence of glutathione-agarose
beads. After elution of bound proteins, they were subjected to
Western blotting with anti-RhoA or anti-Rac1 antibodies.
Confocal Microscopy and Flow Cytometry—For confocal
studies, cells on fibronectin-coated coverslips were fixed with
4% paraformaldehyde (Sigma) in PBS and incubated with pri-
mary antibodies, and after incubation with fluorochrome-con-
jugated secondary antibodies, samples were mounted with
Mowiol, and images were captured using a LEICA TCS-SP2-
AOBS-UV confocalmicroscopewith 63 oil immersion objec-
tive. For labeling intracellular proteins, cells were permeabi-
lized with 0.5% Triton X-100 in PBS before staining with
primary antibodies or with Alexa 633-phalloidin (Molecular
Probes). Displayed images were captured at the same sections
in the different samples. For flow cytometry, cells were incu-
bated with primary antibodies, followed by incubation with
Alexa 488-conjugated secondary antibodies (Molecular
Probes), and analysis in a Coulter Epics XL cytofluorometer.
P3X63 was used as control primary antibody.
Statistical Analyses—Data were analyzed by one-way analy-
sis of variance followed by Tukey-Kramer multiple compari-
sons. In both analyses, the minimum acceptable level of signif-
icance was p 0.05.
RESULTS
Overexpression of E-cadherin in Melanoma Cells Leads to
Inhibition of Chemokine-promoted Invasion—Expression of
CXCR4 on BLM melanoma cells confers strong invasiveness
toward CXCL12 (29). As these cells express very low levels of
E-cadherin (Fig. 1A), we investigated if its overexpression could
influence chemokine-promoted melanoma cell invasion. We
transfected BLM cells with E-cadherin vectors and selected
DC12 and DF11 sublines expressing high levels of E-cadherin
compared with DC11 or mock sublines that expressed low
amounts (Fig. 1A). Control experiments indicated that CXCR4
and 1 integrin expression was not significantly altered in the
different E-cadherin transfectants (data not shown). Overex-
pression of E-cadherin on BLM cells correlated with enhanced
-catenin levels and E-cadherin/-catenin co-precipitation, as
well as with co-localization of these proteins at cell-cell junc-
tions (Fig. 1, A, top and middle, and C). Likewise, E-cadherin
co-localized with -catenin (Fig. 1C) at intercellular junctions.
Similar levels of p120ctn isoforms of 105 and 115 kDa were
detected in mock, DC12, and DF11 sublines (Fig. 1B, left), but
high amounts of this catenin were found associatedwith E-cad-
herin onDC12 cells (Fig. 1B, right), indicating that p120ctn was
recruited by E-cadherin in these transfectants. A low level of
co-precipitated p120ctn was also observed in E-cadherin
immunoprecipitates inmock cells, possibly from the small pop-
ulation of E-cadherin molecules expressed on their mem-
branes. E-cadherin co-localized with p120ctn on DC12 trans-
fectants (Fig. 1C), whereas it displayed a predominant
intracellular distribution in mock cells (data not shown). These
results show that transfected E-cadherin correctly associates
with their binding partners on the membrane of BLM mela-
noma cells.
Expression of E-cadherin on DC12 and DF11 BLM mela-
noma transfectants led to a significant inhibition of their
CXCL12-promoted invasion across Matrigel and type I colla-
gen, as compared with mock transfectant invasion (Fig. 2A).
Impaired invasiveness was directly dependent on E-cadherin,
as invasion of DC12 cells was rescued when expression of this
protein was silenced by RNA interference (Fig. 2B). Mock and
DC12 cultures displayed similar morphologies when plated on
Matrigel, both in the presence of CXCL12 (supplemental Fig.
S1) or in its absence (data not shown), suggesting that impair-
ment in invasion of E-cadherin transfectants was not the result
of differential cell aggregation. Examination of mechanisms
underlying the defective invasion of E-cadherin melanoma
transfectants using time-lapse microscopy performed on
Matrigel in chemotaxis chamber slides revealed that mock
transfectants had higher sustained migration directionality
toward CXCL12 than DC12 cells, which displayed a predomi-
nant random migration. Thus, the cell directionality index
based on the ratio EMD/AMD (see “Experimental Procedures”)
was near 3-fold higher in mock than in DC12 transfectants
(mock, EMD, 109.48  57.34 m; AMD, 207.09  55.3 m;
DC12, EMD, 33.75  19.94 m; AMD, 173.93  62.93 m)
(Fig. 2C; see also supplemental videos 1–4). In addition, when
we tested E-cadherin transfectants in adhesion assays toMatri-
gel layers, or to collagen IV or fibronectin, we observed a partial
impairment in their attachment capability, whichwasmediated
by1 integrins (Fig. 2D). These data suggest that a defect in cell
polarity toward CXCL12 associated with reduced adhesion
shown bymelanoma cells overexpressing E-cadherin represent
likely mechanisms accounting for their impaired invasion in
response to the chemokine.
Defective Invasion of E-cadherin Melanoma Transfectants Is
Due to p190RhoGAP-mediated Impairment in CXCL12-pro-
moted RhoA Activation—Tumor cell migration and invasion are
closely linked to reorganization of the actin cytoskeleton, which is
controlled by Rho GTPases (24). As CXCL12-stimulated mela-
noma cell invasion requires Rho GTPase activation (29), we
first determined whether E-cadherin overexpression in mela-
noma cells affects activation of these GTPases. GTPase assays
revealed that DC12 (Fig. 3A, left) and DF11 (data not shown)
transfectants had defective RhoA activation in response to
CXCL12 compared with mock cells. Conversely, E-cadherin
transfectants displayed higher activation of Rac1 than mock
counterparts (Fig. 3A, right). Moreover, DC12 andDF11 exhib-
ited a lower degree of stress fiber and focal contact formation, as
assessed by F-actin and vinculin staining, respectively (Fig. 3B).
Importantly, when we expressed constitutively active forms of
RhoA (RhoA CA) in DC12 and DF11 melanoma transfectants,
invasion to CXCL12 was recovered to levels similar to those
attained by mock cells expressing RhoA CA (Fig. 3C). These
E-cadherin Expression BlocksMelanoma Invasion to Chemokines
MAY 29, 2009•VOLUME 284•NUMBER 22 JOURNAL OF BIOLOGICAL CHEMISTRY 15149
 at CSIC - Centro de Investigaciones Biológicas on January 5, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
results indicate that defective melanoma cell invasion to
CXCL12 upon E-cadherin expression is based on impaired
RhoA activation.
Increased GAP activity on RhoA represents a potential
mechanism underlying the diminished activation of this
GTPase on E-cadherin melanoma transfectants. A main candi-
date GAP molecule involved in RhoA inactivation and stress
fiber disassembly is p190RhoGAP, which preferentially inacti-
vates RhoA (33, 34). Activation of p190RhoGAP has been
shown to be associated with its tyrosine phosphorylation (35–
37), being Tyr-1105 the main phosphorylated residue (38).
p190RhoGAP displayed higher a degree of tyrosine phospho-
rylation in DC12 and DF11 than in mock transfectants (mean
3.5- and 3.0-fold, respectively, n  3), which was associated
with increased RhoA co-precipitation (Fig. 4A). When cells
were exposed to CXCL12, we detected an increase in
p190RhoGAP phosphorylation in mock cells, although it was
difficult to observe it in DC12 and DF11 transfectants, possibly
due to the fact that they already showed constitutively high
phosphorylation. Moreover, transfection in DC12 cells of
p190RhoGAP siRNA led to recovery of RhoA activation by
CXCL12 to levels close tomock transfectants (Fig. 4B). Increase
in p190RhoGAP tyrosine phosphorylation in DC12 and DF11
cells involved activity by Src familymembers, as it was inhibited
by the Src inhibitor PP2 but not with the control inactive PP3
(Fig. 4C), in agreement with earlier results demonstrating the
key role of Src proteins in p190RhoGAP phosphorylation (38–
41). Furthermore, p190RhoGAP-RhoA association was
reduced in PP2-treated cells, indicating that Src-mediated
phosphorylation of this GAP protein was required for its bind-
ing to RhoA. To investigate if increased GAP activity of
p190RhoGAPonRhoAcould underlie the impairment inDC12
FIGURE 1. Expression of E-cadherin and associatedmolecules onmelanoma transfectants. A, expression of E-cadherin and -catenin on E-cadherin BLM
transfectants was analyzed by Western blotting (top) and co-immunoprecipitation with anti-E-cadherin antibodies (middle). Control loading in immunoblot-
ting was assessed with anti--actin antibodies. Bottom, flow cytometry analyses showing E-cadherin expression on melanoma transfectants. IP, immunopre-
cipitation. B, expression of p120ctn on E-cadherinmelanoma transfectants was assessed by immunoblotting (left). Mock andDC12 cells were transfectedwith
control or p120ctn siRNA and subsequently subjected to immunoprecipitation with anti-E-cadherin antibodies followed byWestern blotting with antibodies
to p120ctn (right). C, confocal microscopy analyses of E-cadherin (Alexa 488) co-localization with -catenin, p120ctn, and -catenin (all Alexa 568) on DC12
melanoma transfectants.
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andDF11 invasion, we knocked down p190RhoGAP and tested
transfectants in invasion assays toward CXCL12. The results
revealed that DC12 and DF11 invasion was recovered to levels
similar to mock cells upon p190RhoGAP silencing (Fig. 4D;
supplemental Fig. S2), indicating that increased activation of
this GAP protein in E-cadherin transfectants accounts for the
reduction in invasion due to inhibition of RhoA activation.
Role of p120ctn in Chemokine-stimulated RhoA Activation
and Invasion ofMelanomaCells—Previousworks have demon-
strated that p120ctn overexpression results in inhibition of
RhoA activation, potentially by a RhoGDI activity of p120ctn
(42, 43), and direct interaction of this catenin with RhoA was
reported both in vitro and in vivo (44, 45). Furthermore, it has
been recently shown that p120ctn and p190RhoGAP can asso-
ciate in E-cadherin complexes in NIH-3T3 fibroblasts, leading
to efficient inhibition of RhoA activation (46). To investigate if
p120ctn is capable of regulating p190RhoGAP-dependent
impairment inRhoAactivation and invasion inmelanoma cells,
we first analyzed whether these two proteins can associate on
E-cadherin melanoma transfectants. Co-precipitation experi-
ments withmelanoma cells transfectedwith control or p120ctn
siRNA revealed that p120ctn and p190RhoGAP were able to
associate in mock, DC12, and DF11 transfectants, indicating
that association occurred independently of the levels of E-cad-
herin expression (Fig. 5A). In addition, CXCL12 did not alter
p120ctn-p190RhoGAP association on melanoma transfectants
(data not shown). p190RhoGAP tyrosine phosphorylation in
DC12 and mock cells was not dependent on p120ctn, as it effi-
ciently took place in p120ctn-silenced cells (Fig. 5B). Further-
more, p120ctn-p190RhoGAP association was observed in PP2-
treated mock and DC12 cells (data not shown). However,
p190RhoGAP-RhoA association was dependent on p120ctn, as
it was largely decreased in p120ctn knockdownDC12 cells (70–
80% reduction, n  3) and to a lesser extent in mock transfec-
tants (30–40% decrease). Whereas p120ctn displayed cell sur-
face localization only on cells overexpressing E-cadherin,
cellular distribution of p190RhoGAP was similar in mock and
DC12 cells (Fig. 5C; see also Fig. 1C for p120ctn). Thus,
FIGURE 2.Overexpression of E-cadherin onmelanoma transfectants leads to impaired invasion to the chemokine CXCL12. A,melanoma transfectants
were subjected to invasion assays toward CXCL12 using Matrigel or type I collagen gels. **, invasion was significantly inhibited, p 0.01, or *, p 0.05, with
respect tomock transfectant invasion (n5).B,DC12 cellswere transfectedwith control or E-cadherin (E-cadh) siRNA, andE-cadherin expressionwas analyzed
by immunoblotting (left), or transfectants subjected to invasion assays. *, invasion was significantly stimulated, p 0.05. C, transfectants were subjected to
time-lapse microscopy experiments on Matrigel using chemotaxis chamber slides. CXCL12 (300 ng/ml) was added on the top reservoir of the chambers, and
migration of individual cells (n 30) was tracked and represented in m (x and y axis) using a common starting point in themiddle of the graph. Shown is a
representative result of three independent experiments.D, transfectants were tested in adhesion assays toMatrigel, collagen IV (Col IV), or fibronectin (FN), in
the presence of control or anti-1mAb, and without (medium) or with CXCL12. Ctr, control. ***, adhesion was significantly inhibited, p 0.001, or *, p 0.05
(n 4).
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p190RhoGAP was found intracellularly, as well as on cell sur-
face protrusions, where it closely co-localized with p120ctn
on DC12 cells (Fig. 5C, top). E-cadherin, p120ctn and
p190RhoGAP co-localized only at cell membrane protrusions
(Fig. 5C, bottom), but not at cell-cell junctions (data not shown).
Cell fractionation assays confirmed the membrane distribu-
tion of p120ctn on DC12 cells, and its preferential associa-
tion with p190RhoGAP at this localization (Fig. 5D). More-
over, plasma membrane fractions displayed higher amounts of
p190RhoGAP and RhoA in DC12 than mock transfectants,
which correlated with increased association of these proteins
on DC12 cell membranes. CD44 and RhoGDI were used as
markers for plasma membrane and cytosolic fractions, respec-
tively. Together these results indicate that p120ctn and
p190RhoGAP can already associate intracellularly under low
levels of E-cadherin expression, and that overexpression of
E-cadherin promotes their association on the cell membrane,
which favors p190RhoGAP-RhoA interaction, leading to inac-
tivation of this GTPase.
To analyze if E-cadherin/p120ctn binding is required for the
regulation of p190RhoGAP and RhoA, we expressed in BLM
melanoma cells a mutant E-cadherin form (E-cadh-764AAA)
that uncouples binding to p120ctn (47). Co-precipitation
experiments indicated that E-cadh-764AAA expression in
BLM cells led to a reduction in the extent of E-cadherin associ-
ation with p120ctn to levels close to mock transfectants, as
compared with E-cadherin wild type (E-Cadh-WT) counter-
parts (Fig. 6A). Control flow cytometry analyses revealed that
E-cadh-WT and E-cadh-764AAA transfectants expressed sim-
ilar levels of cell surface E-cadherin (data not shown). Associa-
FIGURE 3. Defective invasion of E-cadherin melanoma transfectants is due to impairment in CXCL12-promoted RhoA activation. A,melanoma trans-
fectantswere incubated in suspensionwith CXCL12 for the indicated times and subjected toGTPase assays to detect active RhoA (left) and Rac1 (right). Bottom
panel represents densitometer analyses in arbitrary units showing RhoA activation levels (n 3). B, transfectants plated on Matrigel (0.5 g/l) for 1 h were
analyzed by confocal microscopy using Alexa 633-phalloidin for F-actin staining and anti-vinculin mAb to detect focal contacts. C, melanoma cells were
transiently transfected with GFP-fused forms of RhoA wild type (wt) or constitutively active (CA) RhoA, and analyzed for RhoA-GFP and endogenous RhoA
expression (top) or transfectants subjected to Matrigel invasion assays (bottom).WB, Western blot. *, invasion was significantly stimulated, p 0.05 (n 3).
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tion of p120ctn and p190RhoGAP took place independently of
E-cadherin expression levels, in agreement with results
obtained with DC12 cells (see Fig. 5A). Tyrosine phosphoryla-
tion of p190RhoGAP was not affected in E-cadh-764AAA
transfectants (Fig. 6B), confirming that E-cadherin/p120ctn
association is not essential for phosphorylation of theGAP pro-
tein. However, reduced levels of RhoA bound to p190RhoGAP
were found in E-cadh-764AAA transfectants compared with
E-cadh-WT cells, which was associated with a CXCL12-stimu-
lated higher degree of RhoA activation in the mutant E-cad-
herin transfectants in relation with E-cadh-WT cells (Fig. 6, B
and C).
Finally, to determine the potential involvement of p120ctn in
the impaired invasion toward CXCL12 shown by E-cadherin
melanoma transfectants, we tested mock and DC12 cells trans-
fected with control or p120ctn siRNA in Matrigel invasion
assays. Silencing p120ctn in mock transfectants neither
affected their invasion to CXCL12 nor their RhoA activation by
the chemokine (Fig. 7, A and B). Notably, p120ctn-silenced
DC12 cells showed a rescue of RhoA activation and a partial
recovery of invasion. Associatedwith these results, we observed
a decrease in E-cadherin cell surface expression (Fig. 7C). These
data suggest that p120ctn regulate invasion in E-cadherin mel-
anoma transfectants possibly by controlling p190RhoGAP-de-
pendent RhoA activation.
DISCUSSION
Loss or reduction of E-cadherin expression is frequently
associated with acquisition of an invasive phenotype in cancer.
Expression of E-cadherin in normal melanocytes is largely
reduced at initial steps of melanoma progression (8–10). How-
ever, different levels of E-cadherin are found at advanced stages
of the disease (9, 11, 12), raising the possibility that recovery of
E-cadherin expression could influence the invasive potential of
melanoma cells.
Both in vitro and in vivo data indicate that the chemokine
receptor CXCR4 plays crucial roles in the invasion and metas-
tasis of melanoma cells (18, 29). In this study we have used the
FIGURE 4. Knocking down p190RhoGAP leads to recovery of E-cadherinmelanoma transfectant invasion and RhoA activation. A,melanoma transfec-
tants were incubated for 20 min with or without CXCL12, and upon lysis, extracts were subjected to immunoprecipitation (IP) with anti-p190RhoGAP mAb,
followed by Western blotting (WB) using the indicated antibodies. B, mock and DC12 cells were transfected with control or p190RhoGAP (p190) siRNA, and
transfectant lysates were subjected to Western blotting with anti-p190RhoGAP antibodies (top) or to GTPase assays to detect RhoA activation in response to
CXCL12 (bottom gel). Bottom panel represents densitometer analyses in arbitrary units showing RhoA activation levels. C, transfectants were incubated with
PP2 or PP3 (2 h, 3M) and subjected to immunoprecipitation with control or anti-p190RhoGAPmAb, and p190RhoGAP tyrosine phosphorylation and bound
RhoA were analyzed by Western blotting. D, control or p190RhoGAP siRNA melanoma transfectants were tested in Matrigel invasion assays *, invasion was
significantly stimulated, p 0.05 (n 3).
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highly invasive CXCR4 BLM melanoma cell line, which
expresses minimal amounts of E-cadherin, to investigate
whether chemokine-stimulated melanoma cell invasion is
altered upon overexpression of E-cadherin. Here we show that
E-cadherin melanoma transfectants have defective invasion
toward CXCL12 chemotactic cues, as a result of impairment in
cell migration directionality and decreased adhesion. Reduc-
tion in migration and adhesion was independent of potentially
increased cell-cell contacts as a result of E-cadherin expression.
Thus, time-lapsemicroscopy experiments indicated that defec-
tivemigration directionality in E-cadherin transfectants was an
intrinsic property of individual cells. Furthermore, there was
not a general defect in cell response to CXCL12, as these trans-
fectants were capable of up-regulat-
ing their Rac1 activation in response
to the chemokine. Therefore,
decreased cell polarity toward che-
motactic stimuli led to random
migration and reduced invasion of
E-cadherin melanoma transfectants.
Mechanistic characterization of
the impaired invasion revealed that
a defective capacity of E-cadherin
melanoma transfectants to activate
RhoA in response to CXCL12,
because of increased activity of
p190RhoGAP on this GTPase, as
well as a reduction in stress fiber
formation, accounted for the inhibi-
tion in invasion. Thus, expression of
a constitutively active form of RhoA
or silencing p190RhoGAP expres-
sion led to rescue of E-cadherin
melanoma transfectant invasion.
These data suggest that chemokine-
stimulated RhoA activation con-
tributes to the cell polarity response
toward CXCL12 that results in
directed migration and invasion,
and the data indicate that
p190RhoGAP plays a master role in
controlling melanoma cell invasion.
Tyrosine phosphorylation of
p190RhoGAP has been linked with
an increase in its activation (35–37,
41). Melanoma cells overexpressing
E-cadherin exhibited higher levels
of p190RhoGAP tyrosine phospho-
rylation than mock cells, which was
dependent on the activity of Src
proteins, in accordance with their
reported involvement in the phos-
phorylation of the GAP protein
(38–41). The basis for the increased
tyrosine phosphorylation most
likely arises from E-cadherin
engagement in cell-cell contacts
that triggers Src activity at adherens
junctions, as proposed previously (48). Src-dependent phospho-
rylation of p190RhoGAP was required for its association with
RhoA, as it was decreased in PP2-treatedmelanoma cells. Using a
constitutively active form of RhoA (63LRhoA), Noren et al. (48)
reported that 63LRhoA co-precipitated with tyrosine-phospho-
rylated p190RhoGAP in E-cadherinChinese hamster ovary trans-
fectants. Furthermore, phosphorylation of p190RhoGAP at Tyr-
1105 is required for actin stress fiber disassembly (49), a process
associated with RhoA inactivation. Together with our results,
these data stress the importance of p190RhoGAP tyrosine phos-
phorylation for its binding to and inactivation of RhoA.
p120ctn is a E-cadherin binding partner that is also involved
in inhibition of RhoA activation by direct interaction with this
FIGURE 5. p120ctn controls p190RhoGAP association with RhoA in melanoma cells. A and B, melanoma
cells were transfected with control or p120ctn siRNA, and transfectants were subjected to immunoprecipita-
tion with control or anti-p190RhoGAP mAb followed by immunoblotting with antibodies to p120ctn,
p190RhoGAP, phosphotyrosine, or RhoA.C, top,mock andDC12 cells were transfectedwith p190RhoGAP-GFP
and subsequently stained with anti-p120ctn antibodies, followed by analysis by confocal microscopy. Shown
are two different representative cell morphologies as follows: cells with ruffle-like protrusions (left) or with
lamellipodia (right). Bottom left, co-localization of p120ctn-GFP, E-cadherin (Alexa 647), and p190RhoGAP
(Alexa 568) on DC12 cell membrane protrusions. Right, co-localization of p190RhoGAP-GFP and E-cadherin.
White arrows indicate areas of protein co-localization.D, cytoplasmic andmembrane fractions frommelanoma
transfectants were subjected to immunoblotting (left) or to immunoprecipitation (IP) with control or anti-
p190RhoGAP mAb followed by Western blotting with antibodies to p120ctn, p190RhoGAP, or RhoA (right).
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GTPase (50). Overexpression of E-cadherin in melanoma cells
led to a predominant p120ctn-E-cadherin association on the
cell membrane, whereas p120ctn displayed a cytoplasmic local-
ization in mock cells. Interestingly, we found that p120ctn was
associated with p190RhoGAP both in mock and E-cadherin-
expressing melanoma transfectants, but cell membrane co-lo-
calization and association of these proteins was mostly
observed in transfectants overexpressing E-cadherin. Further-
more, we found higher amounts of p190RhoGAP, as well as
RhoA, in plasma membrane fractions from E-cadherin trans-
fectants than from mock cells, although confocal microscopy
analyses revealed similar distribution of p190RhoGAP at cell
lamellipodia in both transfectants. Notably, E-cadherin,
p120ctn, and p190RhoGAP co-localized at cell membrane pro-
trusions, together suggesting that E-cadherin promotes
p120ctn/p190RhoGAP association on the cell membrane.
Silencing p120ctn expression did not affect CXCL12-stimu-
lated mock cell invasion, indicating that a potential inhibition
of RhoA activation by cytoplasmic p120ctn did not significantly
influence this process. However, when p120ctn was knocked
down in melanoma cells overexpressing E-cadherin, a recovery
of chemokine-promoted RhoA activation linked to a large
decrease in p190RhoGAP-RhoA association and a partial res-
cue of invasion was observed. As shown above, silencing
p120ctn or p190RhoGAP expression leads to substantial recov-
ery of RhoA activation in melanoma cells overexpressing
E-cadherin, but only p190RhoGAP
knockdown cells fully rescued the
invasion. Our results suggest that
RhoA inactivation in these cells is
primarily due to p190RhoGAP, but
p120ctn is required for efficient
association between the GAP pro-
tein and RhoA.
On the other hand, E-cadherin-
mediated, Src-dependent tyrosine
phosphorylation of p190RhoGAP in
E-cadherin melanoma transfectants
did not require p120ctn or p120ctn
binding to E-cadherin, as it effi-
ciently took place in cells expressing
a p120ctn-uncoupled E-cadherin
form (E-cadh-764AAA). Src-medi-
ated tyrosine phosphorylation of
p190RhoGAP requires the presence
of p120RasGAP (51), a protein that
directly interacts with the middle
domain of p190RhoGAP (38, 52);
therefore, it is likely that efficient
phosphorylation of p190RhoGAP in
FIGURE 6.Uncoupling E-cadherin-p120ctn interaction impairs p190RhoGAP-RhoAassociation. BLMcells
were transfected with empty vector (mock), wild type E-cadherin (E-Cadh-WT), or E-cadherin-764AAA (E-cadh-
764AAA) and subjected to immunoprecipitation (IP) with anti-E-cadherin or anti-p190RhoGAP antibodies (A
and B) followedbyWestern blotting to the indicated proteins or to RhoAGTPase assays (C).Numbers below the
gel represent densitometer analyses in arbitrary units showing RhoA activation levels.
FIGURE 7.p120ctn regulates CXCL12-promotedmelanomacell invasion andRhoAactivation inmelanomacells overexpressingE-cadherin.Mock and
DC12 were transfected with control or p120ctn siRNA, and transfectants were subjected to Matrigel invasion experiments (A), GTPase assays to detect RhoA
activation (B), or flow cytometry to assess E-cadherin expression (C). *, invasionwas significantly stimulated comparedwith that of DC12 cells transfectedwith
control siRNA, p  0.05 (n  4). Bottom panel in B represents densitometer analyses in arbitrary units showing mean RhoA activation levels from three
independent experiments.
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melanoma cells is contributed by p120RasGAP. Together these
results suggest a model for chemokine-stimulated invasion of
melanoma cells depending on the levels of E-cadherin expres-
sion.When this protein is absent or expressed at very low levels,
GEF activation in response to chemokines overcomes GAP
activity leading to Rho GTPase activation that favors invasion
(30). It is noteworthy that this happens even in the presence of
a preformed cytoplasmic p120ctn-p190RhoGAP-RhoA com-
plex. When E-cadherin is expressed at high levels, tyrosine
phosphorylation of p190RhoGAP is increased, enhancing its
p120ctn-dependent association with RhoA on the cell mem-
brane. This leads to RhoA inactivation, overtaking chemokine-
stimulated GEF activity and finally resulting in defective inva-
sion toward the chemokine, which is based on impaired cell
migration directionality. Our results indicate that E-cadherin-
p120ctn interaction is important to stimulate or to stabilize
p190RhoGAP-RhoA association, as it was significantly reduced
in E-cadh-764AAA transfectants, resulting in a partial rescue of
RhoA activation. It has been shown earlier that when p120ctn
is bound to E-cadherin on the cell membrane, it cannot
directly mediate inhibition of RhoA activation (42), and that
p190RhoGAP can take this role in a Rac- and p120ctn-de-
pendent manner in NIH-3T3 fibroblasts (46). Our data con-
firm the direct involvement of p190RhoGAP in p120ctn-reg-
ulated RhoA inactivation using a cancer cell model,
demonstrating that this process can profoundly affect cell
invasion toward chemokines.
Our results raise the possibility that subpopulations of E-cad-
herin-positive melanoma cells at advanced stages of the disease
could have reduced metastatic potency in response to chemo-
tactic stimuli compared with cells lacking E-cadherin, suggest-
ing that regulation of its expression constitutes an important
therapeutic pathway to limit melanoma dissemination. Indeed,
in a skin reconstruction model, ectopic E-cadherin expression
led to blockade of melanoma cell invasion into dermis (53).
Activation of p190RhoGAP would represent a key step leading
to inhibition of RhoA activation and decreased invasion. In this
regard, a tumor suppressor role has been associated with
p190RhoGAP (54, 55). Further studies are needed to ascertain
its involvement in melanoma cell metastasis.
Acknowledgments—We thank Drs. Amparo Cano, Mireia Dun˜ach,
Antonio García de Hererros, and Miguel A. del Pozo for helpful dis-
cussions and reagents. We also thank María Teresa Seisdedos for
confocal microscopy.
REFERENCES
1. Yagi, T., and Takeichi, M. (2000) Genes Dev. 14, 1169–1180
2. Gumbiner, B. M. (2005) Nat. Rev. Mol. Cell Biol. 6, 622–634
3. Vleminckx, K., Vakaet, L., Jr., Mareel, M., Fiers,W., and van Roy, F. (1991)
Cell 66, 107–119
4. Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Loch-
ner, D., and Birchmeier, W. (1991) J. Cell Biol. 113, 173–185
5. Navarro, P., Gomez, M., Pizarro, A., Gamallo, C., Quintanilla, M., and
Cano, A. (1991) J. Cell Biol. 115, 517–533
6. Thiery, J. P. (2002) Nat. Rev. Cancer 2, 442–454
7. Miller, A. J., and Mihm, M. C., Jr. (2006) N. Engl. J. Med. 355, 51–65
8. Tang, A., Eller,M. S., Hara,M., Yaar,M., Hirohashi, S., andGilchrest, B. A.
(1994) J. Cell Sci. 107, 983–992
9. Cowley, G. P., and Smith, M. E. (1996) J. Pathol. 179, 183–187
10. Hsu, M., Andl, T., Li, G., Meinkoth, J. L., and Herlyn, M. (2000) J. Cell Sci.
113, 1535–1542
11. Danen, E. H., de Vries, T. J., Morandini, R., Ghanem, G. G., Ruiter, D. J.,
and van Muijen, G. N. (1996)Melanoma Res. 6, 127–131
12. Silye, R., Karayiannakis, A. J., Syrigos, K. N., Poole, S., van Noorden, S.,
Batchelor, W., Regele, H., Sega, W., Boesmueller, H., Krausz, T., and Pig-
natelli, M. (1998) J. Pathol. 186, 350–355
13. Chambers, A. F., Groom, A. C., and MacDonald, I. C. (2002) Nat. Rev.
Cancer 2, 563–572
14. Balkwill, F. (2004) Nat. Rev. Cancer 4, 540–550
15. Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E.,
McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., Barrera, J. L.,
Mohar, A., Verastegui, E., and Zlotnik, A. (2001) Nature 410, 50–56
16. Longo-Imedio, M. I., Longo, N., Trevino, I., Lazaro, P., and Sanchez-Ma-
teos, P. (2005) Int. J. Cancer 117, 861–865
17. Scala, S., Ottaiano,A., Ascierto, P. A., Cavalli,M., Simeone, E., Giuliano, P.,
Napolitano, M., Franco, R., Botti, G., and Castello, G. (2005) Clin. Cancer
Res. 11, 1835–1841
18. Murakami, T., Maki, W., Cardones, A. R., Fang, H., Tun Kyi, A., Nestle,
F. O., and Hwang, S. T. (2002) Cancer Res. 62, 7328–7334
19. Ridley, A. J., Schwartz, M. A., Burridge, K., Firtel, R. A., Ginsberg, M. H.,
Borisy, G., Parsons, J. T., and Horwitz, A. R. (2003) Science 302,
1704–1709
20. Jaffe, A. B., and Hall, A. (2005) Annu. Rev. Cell Dev. Biol. 21, 247–269
21. Schmidt, A., and Hall, A. (2002) Genes Dev. 16, 1587–1609
22. Bos, J. L., Rehmann, H., and Wittinghofer, A. (2007) Cell 129, 865–877
23. Olofsson, B. (1999) Cell. Signal. 11, 545–554
24. Sahai, E., and Marshall, C. J. (2002) Nat. Rev. Cancer 2, 133–142
25. Fritz, G., Just, I., and Kaina, B. (1999) Int. J. Cancer 81, 682–687
26. van Golen, K. L., Wu, Z. F., Qiao, X. T., Bao, L. W., and Merajver, S. D.
(2000) Cancer Res. 60, 5832–5838
27. Clark, E. A., Golub, T. R., Lander, E. S., and Hynes, R. O. (2000) Nature
406, 532–535
28. Robledo,M.M., Bartolome, R. A., Longo, N., Rodriguez-Frade, J. M., Mel-
lado, M., Longo, I., vanMuijen, G. N., Sanchez-Mateos, P., and Teixido, J.
(2001) J. Biol. Chem. 276, 45098–45105
29. Bartolome, R. A., Galvez, B. G., Longo, N., Baleux, F., Van Muijen, G. N.,
Sanchez-Mateos, P., Arroyo, A. G., and Teixido, J. (2004) Cancer Res. 64,
2534–2543
30. Bartolome, R. A., Molina-Ortiz, I., Samaniego, R., Sanchez-Mateos, P.,
Bustelo, X. R., and Teixido, J. (2006) Cancer Res. 66, 248–258
31. Bartolome, R. A., Wright, N., Molina-Ortiz, I., Sanchez-Luque, F. J., and
Teixido, J. (2008) Cancer Res. 68, 8221–8230
32. Sander, E. E., van Delft, S., ten Klooster, J. P., Reid, T., van der Kammen,
R. A., Michiels, F., and Collard, J. G. (1998) J. Cell Biol. 143, 1385–1398
33. Settleman, J., Albright, C. F., Foster, L. C., and Weinberg, R. A. (1992)
Nature 359, 153–154
34. Ridley, A. J., Self, A. J., Kasmi, F., Paterson, H. F., Hall, A., Marshall, C. J.,
and Ellis, C. (1993) EMBO J. 12, 5151–5160
35. Chang, J. H., Gill, S., Settleman, J., and Parsons, S. J. (1995) J. Cell Biol. 130,
355–368
36. Nakahara, H., Mueller, S. C., Nomizu, M., Yamada, Y., Yeh, Y., and Chen,
W. T. (1998) J. Biol. Chem. 273, 9–12
37. Arthur, W. T., Petch, L. A., and Burridge, K. (2000) Curr. Biol. 10,
719–722
38. Roof, R. W., Haskell, M. D., Dukes, B. D., Sherman, N., Kinter, M., and
Parsons, S. J. (1998)Mol. Cell. Biol. 18, 7052–7063
39. Ellis, C., Moran, M., McCormick, F., and Pawson, T. (1990) Nature 343,
377–381
40. Bouton, A. H., Kanner, S. B., Vines, R. R., Wang, H. C., Gibbs, J. B., and
Parsons, J. T. (1991)Mol. Cell. Biol. 11, 945–953
41. Fincham, V. J., Chudleigh, A., and Frame, M. C. (1999) J. Cell Sci. 112,
947–956
42. Anastasiadis, P. Z.,Moon, S. Y., Thoreson,M. A.,Mariner, D. J., Crawford,
H. C., Zheng, Y., and Reynolds, A. B. (2000) Nat. Cell Biol. 2, 637–644
43. Noren, N. K., Liu, B. P., Burridge, K., and Kreft, B. (2000) J. Cell Biol. 150,
567–580
E-cadherin Expression BlocksMelanoma Invasion to Chemokines
15156 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 22•MAY 29, 2009
 at CSIC - Centro de Investigaciones Biológicas on January 5, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
44. Magie, C. R., Pinto-Santini, D., and Parkhurst, S. M. (2002) Development
(Camb.) 129, 3771–3782
45. Castano, J., Solanas, G., Casagolda, D., Raurell, I., Villagrasa, P., Bustelo,
X. R., Garcia de Herreros, A., and Dunach, M. (2007) Mol. Cell. Biol. 27,
1745–1757
46. Wildenberg, G. A., Dohn, M. R., Carnahan, R. H., Davis, M. A., Lobdell,
N. A., Settleman, J., and Reynolds, A. B. (2006) Cell 127, 1027–1039
47. Thoreson,M. A., Anastasiadis, P. Z., Daniel, J. M., Ireton, R. C.,Wheelock,
M. J., Johnson, K. R., Hummingbird, D. K., and Reynolds, A. B. (2000)
J. Cell Biol. 148, 189–202
48. Noren, N. K., Arthur, W. T., and Burridge, K. (2003) J. Biol. Chem. 278,
13615–13618
49. Haskell,M. D., Nickles, A. L., Agati, J.M., Su, L., Dukes, B. D., and Parsons,
S. J. (2001) J. Cell Sci. 114, 1699–1708
50. Reynolds, A. B., and Roczniak-Ferguson, A. (2004) Oncogene 23,
7947–7956
51. van der Geer, P., Henkemeyer, M., Jacks, T., and Pawson, T. (1997) Mol.
Cell. Biol. 17, 1840–1847
52. Hu, K. Q., and Settleman, J. (1997) EMBO J. 16, 473–483
53. Hsu,M.Y.,Meier, F. E., Nesbit,M.,Hsu, J. Y., VanBelle, P., Elder, D. E., and
Herlyn, M. (2000) Am. J. Pathol. 156, 1515–1525
54. Tikoo, A., Czekay, S., Viars, C., White, S., Heath, J. K., Arden, K., and
Maruta, H. (2000) Gene (Amst.) 257, 23–31
55. Wolf, R. M., Draghi, N., Liang, X., Dai, C., Uhrbom, L., Eklof, C., Wes-
termark, B., Holland, E. C., and Resh, M. D. (2003) Genes Dev. 17,
476–487
E-cadherin Expression BlocksMelanoma Invasion to Chemokines
MAY 29, 2009•VOLUME 284•NUMBER 22 JOURNAL OF BIOLOGICAL CHEMISTRY 15157
 at CSIC - Centro de Investigaciones Biológicas on January 5, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
SUPPLEMENTAL MATERIAL 
 
Figure 1. Morphological analyses of melanoma cells on Matrigel.  Mock and DC12 
transfectants were incubated for 4h on Matrigel in the presence of CXCL12 (300 ng/ml). Shown 
are representative images from 2 independent experiments.  
Figure 2.  Transfection of melanoma cells with p190 siRNA. Mock, DC12 and DF11 cells 
were transfected with control or p190RhoGAP (p190) siRNA, and transfectant lysates subjected 
to western blotting with anti-p190RhoGAP antibodies or anti-β-actin antibodies to assess 
loading controls. 
 
SUPPLEMENTAL MOVIES. 
 
1A. Migration of Mock cells on Matrigel. Chemokine is located on the top reservoir (See 
Experimental procedures). Shown is 1 frame/10 min. 
1B. Same migration (Mock) showing dots and lines. 
2A. Migration of DC12 cells on Matrigel. Chemokine is located on the top reservoir (See 
Experimental procedures). Shown is 1 frame/10 min. 
2B. Same migration (DC12) showing dots and lines. 
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